ARTICLE | Company News
Cleveland BioLabs, Ministry of Industry and Trade of the Russian Federation cancer news
October 21, 2013 7:00 AM UTC
Cleveland BioLabs said its Russian subsidiary, BioLab 612 LLC, entered into a three-year contract worth RUB149 million ($4.6 million) with the ministry to develop the biotech's Entolimod ( CBLB502) for colorectal cancer (CRC). Entolimod is in preclinical testing for CRC, with Phase Ib testing slated to start mid-2014. The contract requires that BioLab 612 attract matching in-kind funds to the project. Cleveland said it plans to satisfy the requirement by contributing Eurasian patents to BioLab 612. ...